Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Nancy A. Grygiel sold 2,117 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares of the company's stock, valued at $3,094,268.47. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Amgen Price Performance
Shares of NASDAQ:AMGN opened at $311.29 on Friday. The company has a market cap of $166.97 billion, a PE ratio of 24.92, a P/E/G ratio of 2.68 and a beta of 0.60. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The firm has a 50-day simple moving average of $274.51 and a 200 day simple moving average of $281.33. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business's revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.98 earnings per share. On average, sell-side analysts anticipate that Amgen Inc. will post 19.43 EPS for the current year.
Amgen Announces Dividend
Look Who Fired the World’s Richest Man
From Banyan Hill Publishing | Ad
This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S.
And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.
Get the full story here.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.89%. Amgen's dividend payout ratio (DPR) is presently 72.06%.
Analyst Ratings Changes
A number of research analysts have commented on AMGN shares. Barclays upgraded Amgen from an "underweight" rating to an "equal weight" rating and boosted their price objective for the stock from $230.00 to $300.00 in a research note on Friday. StockNews.com upgraded Amgen from a "hold" rating to a "buy" rating in a report on Friday. The Goldman Sachs Group increased their price objective on shares of Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a research report on Wednesday, February 7th. Leerink Partnrs downgraded shares of Amgen from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $271.00 to $310.00 and gave the stock an "equal weight" rating in a research note on Friday. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of "Moderate Buy" and a consensus price target of $305.05.
View Our Latest Stock Report on AMGN
Institutional Trading of Amgen
Several hedge funds have recently bought and sold shares of AMGN. BIP Wealth LLC raised its holdings in shares of Amgen by 2.6% during the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company's stock valued at $360,000 after buying an additional 32 shares during the last quarter. Southland Equity Partners LLC raised its stake in Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company's stock valued at $443,000 after acquiring an additional 34 shares in the last quarter. Acropolis Investment Management LLC boosted its position in Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company's stock worth $288,000 after acquiring an additional 34 shares during the period. Opal Wealth Advisors LLC grew its stake in shares of Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company's stock worth $538,000 after purchasing an additional 34 shares in the last quarter. Finally, Marino Stram & Associates LLC raised its stake in shares of Amgen by 0.7% during the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company's stock valued at $1,332,000 after purchasing an additional 34 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.
About Amgen
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
